REGENXBIO

Business Situation: REGENXBIO sought out the experts at Boston Digital to achieve the primary objectives for their new website: establish a modernized online presence reflective of their innovative spirit, emphasize their competitive edge, and foster a patient-centric atmosphere that inspires engagement.

Our Solution: Our skilled teams joined forces to create a cutting-edge, human-centered digital ecosystem for REGENXBIO that boasts captivating visual design and engaging user experience. We revamped their website into an adaptable, scalable hub that effectively showcases their forward-thinking and highlights the game-changing innovations they bring to the industry.

How We Did It

Performed a comprehensive website audit and competitor analysis to enhance digital growth, refine keyword strategies, and showcase cutting-edge technology.
Transitioned from WordPress to Kentico for enhanced site management and scalability, implemented a dynamic sitemap, and addressed 301s and 404s for improved SEO.
Enhanced mobile responsiveness, improved user experience, and increased website traffic.
Revamped visual design for brand refreshment and user engagement.

Our Approach

Our user experience, design, and development teams joined forces to create a cohesive voice that amplifies the brand’s identity.
We built a patient-focused digital experience with optimal flexibility in design, powerful UX, and top-notch SEO to turn REGENXBIO's website into a dynamic, scalable, easy-to-navigate resource.
The Boston Digital team illustrated REGENXBIO's forward thinking and showcased the innovative science they are changing lives with.
Our team built strategies based on audience behavior to create a digestible digital experience that inspires participation in clinical trials and promotes engagement with educational content- serving each of their audiences’ unique needs.

About REGENXBIO

Since its founding in 2009 by Ken Mills and FOXKISER, REGENXBIO has been a leader in the gene therapy field, driven by an ongoing commitment to develop gene therapies that improve treatment options for people with significant unmet needs. Today, REGENXBIO has end-to-end capabilities in the development of AAV Therapeutics and is advancing the internal pipeline to treat common and rare diseases.

Partnering for a digital-first future

We partnered with REGENXBIO to execute a top-down website redesign that transformed the site into a seamless digital experience fit for the live-saving brand.